AxoGen Inc
NASDAQ:AXGN
AxoGen Inc
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
Revenue Growth: Axogen reported strong 2025 revenue of $225.2 million, up 20.2% year-over-year, with Q4 revenue of $59.9 million growing 21.3%.
Profitability: Adjusted EBITDA for the full year grew 41% to $27.9 million, and the company increased its cash position by $6 million, achieving positive cash flow.
2026 Guidance: Management guided for at least 18% revenue growth in 2026, reaching at least $265.7 million in sales, and expects gross margin to remain in the 74% to 76% range.
Regulatory Milestone: Axogen secured FDA Biologics License Approval for Avance, now the first and only FDA-approved biologic for peripheral nerve repair, granting 12 years of market exclusivity.
Commercial Expansion: The company significantly expanded its sales force in 2025 and plans further hiring, but is still far from full coverage in key markets like extremities and breast.
Operating Expenses: Operating expenses rose due to growth investments and a $7.2 million one-time, non-cash stock-based compensation expense related to the FDA approval.
Coverage & Reimbursement: Commercial coverage for Avance rose above 65%, adding nearly 20 million covered lives, and CMS implemented a favorable new outpatient payment classification for nerve procedures.
Outlook: Management expects continued investment in innovation, commercial infrastructure, and disciplined expense management while maintaining confidence in profitable growth.
